Table 3. Univariate and multivariate analysis of risk factors for RFS and OS in elderly patients.
| Risk factors | RFS (univariate) | RFS (multivariate) | OS (univariate) | OS (multivariate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | ||
| Sex | |||||||||||||
| Female | Ref | Ref | |||||||||||
| Male | 1.061 | 0.668–1.685 | 0.803 | 0.957 | 0.547–1.673 | 0.877 | |||||||
| Age | 1.038 | 0.980–1.099 | 0.206 | 1.085 | 1.015–1.158 | 0.016 | 1.100 | 1.024–1.182 | 0.009 | ||||
| BMI | 0.993 | 0.929–1.062 | 0.847 | 0.980 | 0.904–1.064 | 0.635 | |||||||
| ASA score | |||||||||||||
| 1 | Ref | Ref | |||||||||||
| 2 | 1.066 | 0.550–2.066 | 0.849 | 0.954 | 0.436–2.087 | 0.906 | |||||||
| 3 | 1.318 | 0.635–2.736 | 0.458 | 1.259 | 0.533–2.974 | 0.600 | |||||||
| 4 | 2.550 | 0.565–11.510 | 0.224 | 2.084 | 0.260–16.701 | 0.489 | |||||||
| Extent of gastric resection | |||||||||||||
| Subtotal gastrectomy | Ref | Ref | |||||||||||
| Total gastrectomy | 1.718 | 1.096–2.693 | 0.018 | 1.098 | 0.618–1.915 | 0.751 | |||||||
| Operative approach | |||||||||||||
| Open | Ref | Ref | |||||||||||
| Laparoscopic or robotic | 0.574 | 0.296–1.116 | 0.102 | 0.682 | 0.322–1.445 | 0.318 | |||||||
| TNM staging | |||||||||||||
| II | Ref | Ref | Ref | Ref | |||||||||
| III | 3.865 | 2.198–6.796 | <0.001 | 3.116 | 1.746–5.560 | <0.001 | 3.461 | 1.818–6.589 | <0.001 | 3.502 | 1.822–6.730 | <0.001 | |
| Tumor size | 1.121 | 1.057–1.189 | <0.001 | 1.070 | 1.006–1.138 | 0.031 | 1.034 | 0.943–1.133 | 0.479 | ||||
| Differentiation | |||||||||||||
| Well or moderately | Ref | Ref | |||||||||||
| Poorly or signet ring cell | 1.016 | 0.638–1.617 | 0.946 | 1.360 | 0.773–2.392 | 0.289 | |||||||
| Other | 2.860 | 1.110–7.370 | 0.030 | 1.328 | 0.308–5.724 | 0.703 | |||||||
| Lauren classification | |||||||||||||
| Intestinal | Ref | Ref | |||||||||||
| Diffuse | 1.231 | 0.739–2.051 | 0.425 | 1.805 | 0.600–1.960 | 0.788 | |||||||
| Mixed | 1.059 | 0.464–2.418 | 0.892 | 0.758 | 0.262–2.194 | 0.609 | |||||||
| Lymphatic invasion | 1.576 | 0.904–2.747 | 0.109 | 1.526 | 0.778–2.993 | 0.219 | |||||||
| Vascular invasion | 1.325 | 0.830–2.114 | 0.238 | 1.078 | 0.600–1.936 | 0.803 | |||||||
| AC regimen | |||||||||||||
| S-1 | Ref | Ref | Ref | Ref | |||||||||
| CAPOX | 2.573 | 1.482–4.467 | 0.001 | 1.891 | 1.072–3.333 | 0.028 | 2.986 | 1.568–5.683 | 0.001 | 2.970 | 1.550–5.692 | 0.001 | |
| Completion of planned chemotherapy | |||||||||||||
| Yes | Ref | Ref | Ref | Ref | |||||||||
| No | 1.824 | 1.166–2.852 | 0.008 | 1.645 | 1.050–2.577 | 0.030 | 1.903 | 1.111–3.258 | 0.019 | 1.609 | 0.933–2.774 | 0.087 | |
RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; BMI, body mass index; ASA, American Society of Anesthesiologists; TNM, tumor-node-metastasis; AC, adjuvant chemotherapy; S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin.